Type 2 diabetes susceptibility in the Greek-Cypriot population: Replication of associations with TCF7L2, FTO, HHEX, SLC30A8 and IGF2BP2 polymorphisms
Date
2017Author
Votsi, C.Toufexis, C.
Michailidou, K.
Antoniades, Athos
Skordis, Nicos A.
Karaolis, Minas A.
Pattichis, Constantinos S.
Christodoulou, Kyproula
ISSN
2073-4425Source
GenesVolume
8Issue
1Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
Type 2 diabetes (T2D) has been the subject of numerous genetic studies in recent years which revealed associations of the disease with a large number of susceptibility loci. We hereby initiate the evaluation of T2D susceptibility loci in the Greek-Cypriot population by performing a replication case-control study. One thousand and eighteen individuals (528 T2D patients, 490 controls) were genotyped at 21 T2D susceptibility loci, using the allelic discrimination method. Statistically significant associations of T2D with five of the tested single nucleotide polymorphisms (SNPs) (TCF7L2 rs7901695, FTO rs8050136, HHEX rs5015480, SLC30A8 rs13266634 and IGF2BP2 rs4402960) were observed in this study population. Furthermore, 14 of the tested SNPs had odds ratios (ORs) in the same direction as the previously published studies, suggesting that these variants can potentially be used in the Greek-Cypriot population for predictive testing of T2D. In conclusion, our findings expand the genetic assessment of T2D susceptibility loci and reconfirm five of the worldwide established loci in a distinct, relatively small, newly investigated population. © 2017 by the authors licensee MDPI, Basel, Switzerland.
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Organization Studies: The Fourth Organization Studies Summer Workshop: “Embracing Complexity: Advancing Ecological Understanding in Organization Studies” 5—7 June 2008, Pissouri, Cyprus
Dooley, K. J.; Sandelands, L.; Tsoukas, Haridimos (2007)
-
Article
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: A study of the EORTC early clinical studies group (ECSG)
Pavlidis, Nicholas; Aamdal, S.; Awada, Ahmad; Calvert, H.; Fumoleau, P.; Sorio, R.; Punt, C.; Verweij, J.; Oosterom, A. T. Van; Morant, R.; Wanders, J.; Hanauske, A. R. (2000)Purpose: In a phase II trial, the activity of carzelesin, a cyclopropylpyrroloindole prodrug analog, was assessed. Patients and methods: Carzelesin was used as second- or third-line chemotherapy in patients with breast, ...
-
Article
A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: A study of the EORTC early clinical studies group (ECSG)
Pavlidis, Nicholas; Hanauske, A. R.; Gamucci, T.; Smyth, J. F.; Lehnert, M.; Velde, A. Te; Lan, J.; Verweij, J. (1996)In a multicentre randomized trial of the EORTC-ECSG, we have treated 38 chemotherapy naive patients with advanced non-small-cell lung cancer (NSCLC) with EO9, a novel bioreductive alkylating indoloquinone. The drug was ...